secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-057691
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge
--------------------------------------------------------------------------------

- Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.
- Net loss $141.4M ($2.35/share) vs $52.2M ($0.92/share) prior year; R&D spend $128.7M incl $92.4M IPR&D for LB54640.
- Cash $201M at March 31; closed $150M preferred stock financing April 15 extending runway into 2026.
- On track to submit sNDA for IMCIVREE in pediatric patients 2 to <6 years old in Q2 2024.
- Phase 3 hypothalamic obesity trial top-line data expected H1 2025; Japanese cohort dosing starts Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/0001104659-24-057691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/tm2413330d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer